Last reviewed · How we verify
Ch14.18/CHO
Ch14.18/CHO is a chimeric monoclonal antibody that targets GD2 on neuroblastoma cells and engages immune effector cells to promote antibody-dependent cellular cytotoxicity.
Ch14.18/CHO is a chimeric monoclonal antibody that targets GD2 on neuroblastoma cells and engages immune effector cells to promote antibody-dependent cellular cytotoxicity. Used for High-risk neuroblastoma (in combination with cytokine therapy).
At a glance
| Generic name | Ch14.18/CHO |
|---|---|
| Also known as | Mouse-human chimeric monoclonal anti-GD2 Immunoglobulin G1 (IgG1) antibody, anti GD2 antibody, Dinutuximab beta EUSA, Qarziba®, Chimeric 14.18 anti-GD2 monoclonal antibody produced in Chinese hamster ovary cells |
| Sponsor | University Hospital Southampton NHS Foundation Trust |
| Drug class | Monoclonal antibody (GD2-targeting immunotherapy) |
| Target | GD2 (disialoganglioside) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ch14.18/CHO binds to GD2 (disialoganglioside), a tumor-associated antigen highly expressed on neuroblastoma cells. By cross-linking tumor cells with immune effector cells (NK cells, macrophages, neutrophils), it activates antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), leading to tumor cell destruction. The CHO designation indicates the antibody is produced in Chinese Hamster Ovary cells.
Approved indications
- High-risk neuroblastoma (in combination with cytokine therapy)
Common side effects
- Pain (neuropathic and procedural)
- Fever
- Infection
- Anemia
- Thrombocytopenia
- Hypertension
- Capillary leak syndrome
Key clinical trials
- Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma (PHASE1)
- CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma (PHASE2)
- Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma (PHASE2)
- High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) (PHASE3)
- ch14.18/CHO Bridging Study (PHASE1)
- Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |